Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis

BMC Neurology

Akira Matsumura¹  Masahide Matsuda¹  Takao Tsurubuchi¹  Shingo Takano¹  Hiroyoshi Akutsu¹  Hidehiro Kohzuki¹  Eiichi Ishikawa¹  Narushi Sugii¹  Masashi Mizumoto²  Hideyuki Sakurai² 

[1] Department of Neurosurgery, Faculty of Medicine, University of Tsukuba;Department of Radiation Oncology, Proton Medical Research Center, University of Tsukuba;

关键词: Tumor removal;    Glioma;    Intraoperative MRI;    Immunotherapy;   

DOI  :  10.1186/s12883-021-02318-1

来源: DOAJ

【 摘 要 】

Abstract Glioblastoma (GBM) is a refractory disease with a poor prognosis and various methods, including maximum resection and immunotherapy, have been tested to improve outcomes. In this retrospective study we analyzed the prognostic factors of 277 newly diagnosed GBM patients over 11 years of consecutive cases at our institution to evaluate the effect of these methods on prognosis. Various data, including the extent of removal (EOR) and type of adjuvant therapy, were examined and prognostic relationships were analyzed. The median overall survival (OS) of the entire 277-case cohort, 200 non-biopsy cases, and 77 biopsy cases was 16.6 months, 19.7 months, and 9.7 months, respectively. Gross total removal (GTR; 100% of EOR) was achieved in 32.9% of the cases. Univariate analysis revealed younger age, right side, higher Karnofsky performance status, GTR, intraoperative magnetic resonance imaging (MRI) use for removal, proton therapy, combination immunotherapy, and discharge to home as good prognostic factors. Intraoperative MRI use and EOR were closely related. In the multivariate analysis, GTR, proton therapy, and a combination of immunotherapies, including autologous formalin-fixed tumor vaccine, were the significant prognostic factors. A multivariate analysis of 91 GTR cases showed that immunotherapy contributed to prognostic improvements. The median OS and 5-year OS % values were 36.9 months and 43.3% in GTR cases receiving immunotherapy. In conclusion, GTR, proton therapy, and immunotherapy were good prognostic factors in single-center GBM cases. Tumor vaccine therapy for GTR cases achieved a notably high median survival time and long-term survival ratio, indicating its usefulness in GTR cases.

【 授权许可】

Unknown